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Background: Diabetes is associated with mishandling of thiamine in the kidney and devel-
opment of diabetic nephropathy. The aim of this study is to assess the disturbance of
thiamine and other B-vitamin status of patients with type 2 diabetes in Indonesia.
Methods: One hundred and fifteen patients with type 2 diabetes with and without microalbu-
minuria or albuminuria and 39 healthy people were recruited. After a 2-month washout period
for B-vitamin supplementation, markers of vitamins B1, B6, B9 and B12, were determined.
Results: Fractional excretion of thiamine (22.8 versus 33.5%; P < 0.05) and urinary excretion of
the vitamin B6 degradation product 4-pyridoxic acid (0.081 versus 0.133 mmol/g creatinine,
P < 0.001) was increased in patients with type 2 diabetes with respect to healthy controls.
There was also increased total plasma cobalamin (398 versus 547 pmol/l, P < 0.001) and
holotranscobalamin (74 versus 97 pmol/l, P < 0.001) in patients with type 2 diabetes. In
multiple regression analysis these were linked to HbA1c, duration of diabetes and systolic
blood pressure, and fasting plasma glucose, folate and C-reactive protein, respectively.
Conclusions: There was renal mishandling of thiamine, increased degradation of vitamin B6
and cytosolic metabolic resistance to vitamin B12 in patients with type 2 diabetes in Indonesia.
# 2011 Elsevier Ireland Ltd. All rights reserved.
* Corresponding author. Tel.: +44 24 7696 8594; fax: +44 24 7696 8653/594.
E-mail address: P.J.Thornalley@warwick.ac.uk (P.J. Thornalley).
Abbreviations: ACR, albumin creatinine ratio; ALT, L-alanine:2-oxoglutarate aminotransferase; ARBs/ACEIs, angiotensin receptor
blocker/angiotensin converting enzyme inhibitor; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein;
CVD, cardiovascular disease; DN, diabetic nephropathy; DTT, dithiothreitol; FPG, fasting plasma glucose; FEMetabolite, fractional excretion
of designated metabolite; eGFR, estimated glomerular filtration rate; LC–MS/MS, liquid chromatographic with tandem mass spectrometric
detection; MMA, methylmalonate; 4-PA, 4-pyridoxic acid; PL, pyridoxal; PLP, pyridoxal-50-phosphate; PM, pyridoxamine; PMP, pyridox-
amine-50-phosphate; PN, pyridoxine; RBC, red blood cell; TFA, trifluoroacetic acid; tHcy, total plasma homocysteine ([homocystei-
ne] + 2  [homocystine]); TK, transketolase; TMP, thiamine monophosphate; TPP, thiamine pyrophosphate; sVCAM-1, soluble vascular
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The Southeast Asia and the Western Pacific regions are at the
forefront of the current epidemic of type 2 diabetes. There is
approximately 7 million people in Indonesia with diabetes,
mostly type 2 diabetes, and this is predicted to rise to 12
million by 2020 [1]. There will likely be a subsequent increased
burden of vascular complications of diabetes, including
diabetic nephropathy (DN), in this population [2,3]. It is
predicted that 25% of newly diagnosed patients with type 2
diabetes will develop early stage DN within the next 10 years
[4]. The development of DN exacerbates the increased risk of
cardiovascular disease (CVD) in type 2 diabetes [5]. Improve-
ments in understanding of mechanism of development of DN
and related treatment are required to decrease morbidity and
premature mortality in this increasing high risk group.
Strategies to prevent DN including nutritional and thera-
peutic support related to B-vitamin supplements have
recently emerged. Two independent intervention studies with
therapeutic supplements of thiamine (vitamin B1) have shown
decrease in urinary albumin excretion and reversal of
microalbuminuria in patients with type 2 diabetes [6,7]. This
treatment may work, at least in part, by countering the effects
of increased renal clearance of thiamine found in clinical
diabetes [8]. Plasma levels of pyridoxal-50-phosphate (PLP), a B6
vitamer, were linked inversely to the vascular inflammatory
marker C-reactive protein (CRP) in clinical DN [9]. Supplemen-
tation of vitamin B6 by treatment with pyridoxine improved
flow-mediated dilatation in type 1 diabetes [10]. Vitamin B6,
vitamin B9 (folate) and vitamin B12 (cobalamin) have been
studied in relation to increased homocysteine and risk of CVD
[11–13]. In studies of interactions with drug therapy, short-
term and long-term treatment with metformin has been
linked to decreases in folate (5–7%) and vitamin B12 (14–19%)
levels in patients with type 2 diabetes receiving metformin
therapy [14,15]. A recent finding suggested co-supplementa-
tion with B6, B9 and B12 in patients with type 2 diabetes and
advanced DN exacerbates decline in renal function [13] – an
association possibly linked to adverse effects of accumulation
of folate and cyanide (from cyanocobalamin treatment) in
patients with impaired renal function [16,17].
We hypothesised that there may be increased clearance
and washout of thiamine in patients with type 2 diabetes in
South East Asia and chose to study patients and people
Indonesia as typical of the region. We also investigated
disturbances in other B-vitamins. In this report we describe
the outcome of a multicenter study of B-vitamin status of
patients with type 2 diabetes with and without microalbumi-
nuria and albuminuria and healthy people in Indonesia.
2. Methods
2.1. Patients
Patients with type 2 diabetes were recruited from those
attending the diabetes clinics at CiptoMangunkusumo Hospi-
tal, Jakarta, Soetomo Hospital, Surabaya, Hasan Sadikin
Hospital, Bandung and Dr Wahidin Sudirohusodo Hospital,Please cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
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implemented in the study is defined by the Asian-Pacific Type
2 Diabetes Policy Group and endorsed by the International
Diabetes Federation [18]. Inclusion criteria were: diabetic
patients – type 2 diabetes with normoalbuminuria (albumin/
creatinine ratio ACR < 22 and <31 mg/g for men and women,
respectively), microalbuminuria (ACR 22–220 and 31–220 mg/g
for men and women, respectively) and albuminuria (ACR
>220 mg/g and plasma creatinine <2 mg/dl) matched for age
(45–65 years) and gender – including a within group gender
balance, diabetes duration 5 years, HbA1c < 10% and BMI 19–
40 kg/m2). Urinary albumin excretion criteria were confirmed
on at least 2 occasions (pre-screening and study entry). A
group of healthy people of the same social background as the
patients with type 2 diabetes were also recruited. Exclusion
criteria were: allergy or intolerance to thiamine, pyridoxine or
cobalamin, participation in another clinical study within the
last 30 days, women who were pregnant, breast feeding or of
child bearing potential not using adequate contraceptive
precautions; for diabetic patients, chronic renal insufficiency
(plasma creatinine 2 mg/dl) [19], liver diseases (abnormal
liver function tests – serum albumin, alanine transaminase,
aspartate transaminase), anemia (Hb < 120 g/l), tuberculosis
and severe CVD (angina, myocardial infarction and normal
electrocardiogram within 2 months of enrolment). Medication
use of the patients with type 2 diabetes was: metformin 60%,
a-glycosidase inhibitor 28%, sulfonylurea 54%, insulin 18%,
angiotensin receptor blockers/angiotensin converting enzyme
inhibitors (ARBs/ACEIs) 15% and statins 15%. Assessments for
meeting the inclusion criteria were made at the initial pre-
screening visit to the participating clinics.
To eliminate effects of vitamin supplementation, the study
involved pre-screening where meeting of inclusion and
exclusion criteria was assessed followed by a washout period
of 2 months for supplements with thiamine, vitamin B6, folate
and vitamin B12. After the washout period, further peripheral
venous blood (with heparin anticoagulant) and urine samples
were collected after overnight fasting. Plasma and red blood
cell (RBC) fractions were prepared immediately and stored at
80 8C until analysis. Ethical approval for the study was given
by the University of Warwick Bioethics Committee, UK, and
local ethical approval committees at the recruiting hospitals in
Indonesia. Enrolment in the study was with informed consent.
The reported investigations have been carried out in accor-
dance with the principles of the Declaration of Helsinki as
revised in 2000.
2.2. Biochemical measurements
Thiamine status was assessed by measurement of thiamine,
thiamine monophosphate (TMP) and thiamine pyrophosphate
(TPP) in plasma, RBCs and urine, and RBC transketolase (TK)
activity – all as previously described [8]. B6 vitamers (pyridox-
ine PN, pyridoxal PL, pyridoxal-50-phosphate PLP, pyridox-
amine PM, pyridoxamine-50-phosphate PMP and 4-pyridoxic
acid 4-PA) were determined in plasma, RBCs and urine by
HPLC with post-column derivatization [20]. RBC activity of L-
alanine:2-oxoglutarate aminotransferase (ALT) and aspartate
aminotransferase (AST) were determined spectrophotometri-
cally using commercial kits (Thermo Fisher Scientific, Lough-f B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
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determined by electrochemiluminescent immunoassay using
a Roche Elecsys E170 analyzer (Roche Diagnostics UK, Burgess
Hill, UK). Plasma holotranscobalamin or ‘‘active vitamin B12’’
was determined by immunoassay using an Abbott AXSYM
analyser (Abbott Diagnostics, Maidenhead, UK).
Total plasma homocysteine (tHcy) and methylmalonic acid
(MMA) were determined by stable isotopic dilution analysis
liquid chromatography with tandem mass spectrometric
detection (LC–MS/MS). Stock solutions of homocystine
(1 mg/ml in 100 mmol/l HCl), MMA (1 mg/ml in water),
[3,3,30,30,4,4,40,40-d8]homocystine (1 mg/ml in 100 mmol/l
HCl) and [methyl-d3]MMA (1 mg/ml in water; Cambridge
Isotopes, Andover, MA, USA) and 500 mol/l dithiothreitol
(DTT) in water were prepared and stored in 20 8C. The
working calibration solution was prepared before analysis and
further diluted to obtain calibration curve in the range 0–
5 nmol homocystine and 0–40 pmol MMA and 100 pmol
homocystine-d8 and MMA-d3. Isotopic standard (10 mmol/l
d8-homocystine and 10 mmol/l d3-MMA; 10 ml) was added to
plasma (50 ml) and calibrators (50 ml). DTT (5 ml) was added and
samples left at room temperature for 30 min on ice to reduce
homocystine to homocysteine. Samples were deproteinized
by ultrafiltration over 10 kDa microspin filters (10,000  g,
60 min, 4 8C). The ultrafiltrate (50 ml) was then analysed by LC–
MS/MS system. The detection conditions were (molecular
ion > fragment ion; m/z): homocysteine, 136.1 > 90.1 and d4-
Hcy, 140.1 > 94.1 (collision energy 11.0 eV and cone voltage
18.0 V, positive ion mode); MMA, 117.0 > 73.0 and d3-MMA,
120.0 > 76.0 (collision energy 7 eV and cone voltage 20 V,
negative ion mode). LC–MS/MS was performed using a Waters
Acquity UPLC system with a Quattro Premier XE tandem mass
spectrometric detector. For chromatographic separation, two
Hypercarb columns (5 mm particle size, dimensions
50 mm  2.1 and 250 mm  2.1 mm) in series were used with
a 10 mm  2.1 mm guard column (Thermo Fisher). The mobile
phase components were: (A) 0.1% trifluoroacetic acid (TFA) in
water and (B) 0.1% TFA in 50% acetonitrile. The elution
gradient programme was: 0–10 min, 0–100% B, 10–15 min,
100% B. The flow rate was 0.2 ml/min. Electrospray ionization
was performed with source temperature 120 8C, desolvation
gas temperature 350 8C, cone gas and desolvation gas flows 102
and 860 L/h, respectively, capillary voltage 3.0 kV and argon
collision gas 5  103 mBar. Retention times, limits of quanti-
fication, inter-batch coefficients of variation and recoveries
were: homocysteine – 8.8 min, 5 pmol, 1.6% and 106%; MMA –
11.6 min, 2 pmol, 4.3% and 105%.
Clinical indicators of metabolic control were determined:
fasting plasma glucose, HbA1c, plasma total cholesterol and
HDL cholesterol and triglycerides. LDL cholesterol (LDL) was
deduced by the Friedewald equation [21]. Nephropathy status
was assessed by measurement of urinary albumin by gel
permeation liquid chromatography [22]. Urinary and plasma
creatinine were determined by the creatininase method.
Markers of endothelial dysfunction, low grade inflammation
and renal function – soluble vascular adhesion molecule-1
(sVCAM-1), CRP and cystatin c were determined by enzyme-
linked immunosorbent assay (R and D Systems, Abingdon,
UK). eGFR was deduced from plasma cystatin c concentration:
eGFR = 86.7/[cystatin c (mg/l)]  4.2 [23].Please cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
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Data are mean  SD for parametric data and median (lower–
upper quartile) for non-parametric data. Significance of
difference between mean changes was assessed by Student’s
t test and one-way ANOVA. Significance of difference between
median changes was assessed by Mann–Whitney-U test and
Kruskal–Wallis test. Bivariate correlate analysis was per-
formed by the non-parametric Spearman method. Factors
linked to markers of B-vitamin dysfunction in patients with
type 2 diabetes were explored by multiple linear regression
analysis. Bonferroni correction was applied to the 4 vitamin B6
vitamers (PN, PL, PLP and PMP; significance for P < 0.0125) and
two vitamin B12 analytes (total plasma vitamin B12 and
holotranscobalamin; significance for P < 0.025)
3. Results
3.1. Characteristics of patients with type 2 diabetes and
healthy people
The characteristics of patients with type 2 diabetes and
healthy people recruited for this study are given in Table 1.
Study groups of patients with type 2 diabetes had a slightly
higher mean age than the healthy controls. For healthy people
included in the study, 2 subjects had HbA1c = 6.5% and were
excluded from data analysis as meeting the criterion for
diagnosis of diabetes by current international guidelines [24].
For the remaining healthy subjects, 22 of 37 had HbA1c in the
range 5.7–6.4%, indicative of pre-diabetes by current interna-
tional guidelines [24]. For patients with type 2 diabetes, 51%
had good glycemic control (HbA1c  7.0), 46% had moderate
glycemic control (HbA1c > 7.0 and 10.0) and only 3% had poor
glycemic control; and 31% had hypertension. They had a
slightly higher BMI than the healthy controls that was mostly
due to high BMI in the albuminuria group. Overall, obesity
(BMI > 30 kg/m2) was low: one healthy control and 11 (10%)
patients with type 2 diabetes were obese. All study groups of
patients with type 2 diabetes had a similar duration of
diabetes. General health was assessed by blood hemoglobin,
plasma albumin and plasma ALT and AST. Blood hemoglobin
was 120 g/l for all male subjects in the study. For women, 70
of the 84 females included in the study had blood hemoglobin
content 120 g/l, 13 had blood hemoglobin content 110 and
<120 g/l, and one had low blood hemoglobin content (70 g/l) at
pre-screening. Plasma ALT and AST was within the normal
range in 148 and 143 subjects, respectively. The 14 patients
with blood hemoglobin <120 g/l and 5 patients with abnormal
plasma ALT and AST were retained in the analysis as other
biochemical indicators were not dissimilar from patients
meeting the inclusion criteria.
Markers of vascular inflammation were surprisingly little-
changed in patients with type 2 diabetes. For CRP, 7% of
healthy controls and 8% of patients with diabetes had levels
higher than the upper limit of the normal range (4.50 mg/l);
and for sVCAM-1, 10% of healthy controls and 11% of patients
with diabetes had levels higher than the upper limit of the
normal range (0.88 mg/l). There were small increases of
plasma CRP in patients with diabetes and microalbuminuriaf B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
Table 1 – Characteristics of subjects recruited for this study.
Variable Healthy subjects Diabetes
Normoalbuminuria Microalbuminuria Albuminuria
N 37 53 36 26
Gender (M/F) 17/20 23/30 16/20 13/13
Age (years) 52  6 57  5*** 58  4*** 57  6**
Duration of diabetes (years) – 8 (5–14) 7 (5–10) 8 (6–10)
BMI (kg/m2) 23.6  2.9 24.6  3.6 24.9  3.4 26.2  3.5**
Plasma glucose (mM) 4.94  0.60 6.64  2.02*** 8.31  3.06*** 8.53  3.37***
HbA1c (%) 5.73  0.42 6.79  1.26*** 7.36  1.21*** 7.70  1.15***
GFR (ml/min) 102  29 108  33 96  26 83  27*
ACR (mg/g) 4.3 (1.9–9.4) 7.8 (2.53–11.6) 80.9 (45.3–136.6)***,yyy 891.4 (486.7–2364.9)***,yyy,zzz
Plasma creatinine (mM) 74  16 73  20 80  24 93  31**,y
Systolic BP (mmHg) 115  11 123  14** 131  14***,y 127  16**
Diastolic BP (mmHg) 78  7 79  8 83  9* 80  9*
Total cholesterol (mg/dl) 202  38 197  34 204  40 209  50
LDL (mg/dl) 128  33 119  28 121  31 128  42
HDL (mg/dl) 52  10 52  11 49  12 47  9*,y
TG (mg/dl) 103 (76–138) 119 (82–165) 148 (106–204)**,y 147 (101–175)*
Hb (g/l) 139  12 137  13 135  13 139  19
Albumin (g/l) 45  2 46  2 46  3 43  9
Plasma ALT (U/ml) 24  10 24  15 25  13 24  16
Plasma AST (U/ml) 25  6 25  10 26  9 25  8
CRP (mg/l) 1.01 (0.49–2.20) 1.08 (0.38–1.95) 2.15 (0.64–3.05)*,y 1.46 (0.58–2.12)
sVCAM-1 (mg/l) 0.56 (0.48–0.70) 0.56 (0.47–0.65) 0.60 (0.50–0.73) 0.67 (0.78–0.89)**,yyy
* Significance: P < 0.05 with respect to healthy subjects.
** Significance: P < 0.01 with respect to healthy subjects.
*** Significance: P < 0.001 with respect to healthy subjects.
y Significance: P < 0.05 with respect to patients with type 2 diabetes and normoalbuminuria.
yyy Significance: P < 0.001 with respect to patients with type 2 diabetes and normoalbuminuria.
zzz Significance: P < 0.001 with respect to patients with type 2 diabetes and microalbuminuria.
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albuminuria. Use of ARBs/ACEIs and statin therapy was
relatively low – although this is still common in developing
countries linked to limited access to medicines [25].
3.2. Thiamine-related variables
Median plasma thiamine concentration was 10.7 nM in
healthy people and was not changed significantly in patients
with diabetes with or without microalbuminuria or albumin-
uria. Similarly RBC concentration of thiamine and activity of
TK were unchanged in patients with diabetes. Urinary
excretion of thiamine and FEthiamine were increased 62% and
50%, respectively, in patients with type 2 diabetes and
normoalbuminuria (Table 2). Comparison of healthy subjectsTable 2 – Thiamine-related variables.
Variable Healthy subjects 
Nor
Plasma thiamine (nM) 10.7 (8.5–12.9) 11.5
RBC thiamine (nmol/g Hb) 0.011 (0.006–0.020) 0.01
RBC TK activity (U/g Hb) 0.34  0.11 0.35
Urinary thiamine (mmol/g creatinine) 0.29 (0.21–0.49) 0.47
FEthiamine (%) 22.8 (17.0–34.7) 34.2
* Significance: P < 0.05 with respect to healthy subjects.
Please cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
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urinary excretion thiamine was not increased in patients with
type 2 diabetes whereas FEthiamine was increased (22.8 versus
33.5%; P < 0.05).
3.3. Vitamin B6-related variables
B6 vitamers, PN, PL, PLP and PMP were detected in plasma. In
healthy people, PL was the quantitatively most important B6
vitamer analyte (78% total plasma B6 vitamers) and others
minor – PLP 16%, PN 5% and PMP 1%. Plasma concentrations of
B6 vitamers in healthy people were (nM): PN 3.50 (2.72–5.45), PL
53.5 (45.1–67.3), PLP 10.7 (9.4–16.6) and PMP 0.89 (0.61–1.22).
Plasma concentrations of PL and PLP was increased in patients
with diabetes (P < 0.05, Kruskal–Wallis); plasma PL wasDiabetes
moalbuminuria Microalbuminuria Albuminuria
 (8.4–17.6) 12.3 (6.7–22.3) 10.0 (6.1–12 .3)
3 (0.007–0.024) 0.014 (0.008–0.024) 0.011 (0.006–0.022)
  0.14 0.35  0.14 0.29  0.10
 (0.26–1.18)* 0.36 (0.16–0.76) 0.26 (0.15–0.51)
 (19.9–54.7)* 34.0 (21.1–41.9) 27.8 (15.6–58.3)
f B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
Table 3 – Vitamin B6-related variables.
Variable Healthy subjects Diabetes
Normoalbuminuria Microalbuminuria Albuminuria
Plasma PL (nM) 53.5 (45.1–67.3) 60.3 (47.5–75.0) 69.4 (46.4–91.5) 68.4 (52.8–98.6)*
Plasma PLP (nM) 10.7 (9.4–16.6) 18.6 (11.7–34.4)** 15.5 (11.7–36.7)* 13.1 (9.4–19.8)
Plasma 4-PA (nM) 7.4 (5.8–12.0) 13.4 (9.5–24.4)*** 12.8 (10.0–23.2)*** 15.1 (11.5–25.2)***
Urinary PL (mmol/g creatinine) 1.00 (0.77–1.14) 1.11 (0.92–1.28) 1.08 (0.98–1.41) 1.20 (0.97–1.57)**
Urinary 4-PA (mmol/g creatinine) 0.081 (0.063–0.098) 0.142 (0.097–0.201)*** 0.137 (0.098–0.201)*** 0.106 (0.084–0.183)**
(% total B6 excretion) 6.5 (5.4–9.0) 10.4 (6.5–13.6)
** 9.2 (6.2–13.1)* 6.9 (4.0–9.9)
* Significance: P < 0.05 with respect to healthy subjects.
** Significance: P < 0.01 with respect to healthy subjects.
*** Significance: P < 0.001 with respect to healthy subjects.
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plasma PLP was increased in patients with diabetes and
normoalbuminuria or microalbuminuria (Table 3).
B6 vitamers were detected in RBCs. In healthy people, PL
and PLP were the quantitatively most important B6 vitamer
analytes (31% and 34%, respectively, of total B6 vitamers) and
other vitamers minor – PN 17% and PMP 18%. B6 vitamer
concentrations in RBCs of healthy people were (nmol/g Hb): PN
0.027 (0.015–0.045), PL 0.049 (0.030–0.078), PLP 0.054 (0.039–
0.070) and PMP 0.028 (0.020–0.040). The levels were not
changed significantly in patients with diabetes with or without
microalbuminuria or macroalbuminuria. Related to this, RBC
activities of PLP-dependent enzymes, ALT and AST, were
7.89  3.42 and 27.6  9.3 U/g Hb respectively, in healthy
people and were also not changed in patients with diabetes
(data not shown).
B6 vitamers were detected in urine of healthy people. PL
was the major B6 vitamer excreted (95% total B6 vitamer
excretion), with others showing only minor excretion – PN 4%,
PLP 1% and PMP <1%. Urinary excretions of B6 vitamers in
healthy people were (mmol/g creatinine): PN 0.040 (0.029–
0.056), PL 1.00 (0.77–1.14), PLP 0.006 (0.001–0.053), 0.0032
(0.0020–0.0048). Urinary excretion of PL was increased in
patients with diabetes, with respect to healthy controls
(P < 0.05, Kruskal–Wallis), which was attributed to increased
urinary excretion of PL in patients with diabetes and
albuminuria (Table 3). Fractional excretion of B6 vitamers in
healthy people was (%): FEPN 9.0 (6.1–17.0), FEPL 15.4 (13.4–16.7),
FEPLP 0.34 (0.07–1.85) and FEPMP 2.7 (1.9–5.1). Fractional
excretion of B6 vitamers was not changed significantly inTable 4 – Folate, total homocysteine and vitamin B12-related v
Variable Healthy subjects 
Nor
Plasma folate (nmol/l) 30.4  7.5 32.7
Total plasma cobalamin (ng/l) 398 (299–604) 545 
Plasma holotranscobalamin (pmol/l) 74 (51–92) 86 (
Plasma tHcy (mmol/l) 10.8 (8.6–14.6) 16.3
Plasma MMA (mmol/l) 0.19 (0.13–0.29) 0.19
* Significance: P < 0.05 with respect to healthy subjects.
** Significance: P < 0.01 with respect to healthy subjects.
*** Significance: P < 0.001 with respect to healthy subjects.
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or albuminuria (data not shown).
The major degradation product of vitamin B6, 4-PA, was
detected in plasma, RBCs and urine. Plasma 4-PA was
increased in patients with diabetes with or without micro-
albuminuria or albuminuria. RBC content of 4-PA was not
changed in patients with diabetes. Urinary excretion of 4-PA
was increased in all diabetic patient groups (Table 3).
3.4. Folate, total homocysteine and vitamin B12–related
variables
The concentration of folate in plasma was not changed in
patients with diabetes with or without microalbuminuria,
with respect to healthy people, but was increased 14% in
patients with diabetes and albuminuria. Total plasma cobala-
min was increased 37% in patients with diabetes and
microalbuminuria. Plasma holotranscobalamin was increased
36% and 47% in patients with diabetes and microalbuminuria
and albuminuria, respectively. Plasma tHcy was increased in
patients with diabetes independent of ACR status whereas
MMA was not increased in patients with type 2 diabetes (Table
4). Criteria for diagnosing vitamin B12 deficiency are plasma
holotranscobalamin <50 pmol/l and plasma MMA >0.27 mmol/
l [26]. Applying these criteria to the study groups herein, the
proportion of patients with type 2 diabetes and healthy
subjects with vitamin B12 deficiency was 7% and 14%,
respectively.
Bivariate correlation analysis and multiple linear regres-
sion analysis for B-vitamin-related variables in patients withariables.
Diabetes
moalbuminuria Microalbuminuria Albuminuria
  8.4 33.8  9.8 34.7  10.2*
(380–748) 545 (430–867)** 568 (397–682)
65–148) 101 (74–210)** 110 (91–200)***
 (10.4–33.2)** 19.2 (10.0–32.1)*** 18.8 (12.0–28.1)***
 (0.14–0.29) 0.20 (0.16–0.26) 0.20 (0.15–0.25)
f B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
Table 5 – Multiple linear regression analysis of markers of B-vitamin disturbance in patients with type 2 diabetes.
Dependent variable Independent variable Unstandardized
coefficient
Standardized
coefficient
P
FEThiamine (%) HbA1c (%) 7.12  3.23 0.21 0.032
Urinary 4-PA (mmol/g creatinine) Duration of diabetes (years) 0.08  0.03 0.23 0.014
Systolic blood pressure (mmHg) 0.02  0.01 0.19 0.045
Constant 2.99  1.42 0.038
Plasma holotranscobalamin (pmol/l) Fasting plasma glucose (mmol/l) 16.4  3.8 0.38 <0.001
Folate (ng/l) 2.55  1.09 0.20 0.022
CRP (mg/l) 9.55  4.77 0.17 0.048
Variables included in the models (excluding interrelated dependent variables in different statistical models): age, duration of diabetes, fasting
plasma glucose, HbA1c, TC, LDL, HDL, TG, systolic and diastolic blood pressure, ACR, CRP, sVCAM-1, folate, GFR.
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metabolites, plasma thiamine correlated positively with
urinary thiamine and RBC TK (r = 0.74, P < 0.001 and r = 0.26,
P < 0.01, respectively). In multiple regression analysis, in-
creased FEthiaminewas selected as the dependent variable since
it is a critical marker of renal mishandling of thiamine in type 2
diabetes [8,27]. There was a positive regression of FEthiamine on
HbA1c in patients with type 2 diabetes (Table 5).
In bivariate correlation analysis of B6 vitamers, there were
positive correlations of plasma PLP with plasma PL and 4-PA
(r = 0.44 and 0.70, P < 0.001), RBC PLP, PL and 4-PA (r = 0.70, 0.53
and 0.37; P < 0.001) and with urinary 4-PA (r = 0.70, P < 0.001).
Plasma PL correlated positively with plasma sVCAM-1 (r = 0.29,
P < 0.01) and urinary 4-PA correlated positively with HbA1c
(0.26, P < 0.01). Increased urinary excretion of 4-PA in patients
of type 2 diabetes is a marker of increased degradation of
vitamin B6. In multiple regression analysis, urinary excretion
of 4-PA was selected as the dependent variable since it was a
marker of increased vitamin B6 degradation in type 2 diabetes.
There were positive regressions of urinary excretion of 4-PA on
duration of diabetes and systolic blood pressure in patients
with type 2 diabetes (Table 5).
In bivariate correlation analysis of vitamin B12-related
variables, plasma total vitamin B12 correlated positively with
holotranscobalamin (r = 0.76, P < 0.001), plasma glucose and
HbA1c (r = 0.26 and 0.25, respectively; P < 0.01); and correlated
negatively with plasma MMA (r = 0.38, P < 0.001). Plasma
holotranscobalamin had similar correlates. Folate correlated
positively with TG (r = 0.26, P < 0.01). In multiple regression
analysis, plasma holotranscobalamin was selected as the
dependent variable since it was a marker of vitamin B12
disturbance in type 2 diabetes. There were positive regressions
of plasma holotranscobalamin on fasting plasma glucose and
CRP and a negative regression with plasma folate in patients
with type 2 diabetes (Table 5).
Other significant outcomes in bivariate correlation analysis
were: plasma sVCAM-1 correlated positively with ACR
(r = 0.40, P < 0.001) and negatively with eGFR (r = 0.27,
P < 0.01); and plasma CRP correlated positively with BMI and
TG (r = 0.29, P < 0.01 and r = 0.25, P < 0.01, respectively).
3.5. Effect of drug treatment on B-vitamin status
Patients with type 2 diabetes receiving treatment with
metformin did not have any significant change in B-vita-
min-related variables, compared to patients with type 2Please cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
renal status, glycemic control and vascular inflammation. Diab Res Clindiabetes not treated with metformin. Patients with type 2
diabetes receiving treatment with a-glucosidase inhibitors
had decreased plasma holotranscobalamin, compared to
patients not treated with a-glucosidase inhibitors: 80 (66–
109) versus 104 (78–209) pM, P < 0.05. They also had decreased
RBC PLP concentration: 0.042 (0.031–0.064) versus 0.057 (0.040–
0.088) pmol/mg Hb (P < 0.05). Patients with type 2 diabetes
receiving treatment with sulfonylurea hypoglycaemic agents
had decreased plasma holotranscobalamin, compared to
patients not treated with sulfonylureas: 90 (68–113) versus
119 (78–213) pM, P < 0.05. Patients with 2 diabetes receiving
treatment with insulin did not have any significant change in
B-vitamin-related variables. Patients with 2 diabetes receiving
treatment with ARBs/ACEIs had increased plasma thiamine
concentration compared to patients with 2 diabetes not
treated with ARBs/ACEIs: plasma thiamine concentration –
15.8 (10.8–31.6) versus 10.6 (6.6–16.7 nM, P < 0.01. Patients
receiving treatment with statins had expected decreased
plasma total cholesterol (170  28 versus 205  38 mg/dl,
P < 0.01) and LDL cholesterol (93  26 versus 124  29 mg/dl,
P < 0.001) but no significant difference of B-vitamin-related
variables.
4. Discussion
Countering the effects of increased renal clearance of
thiamine in clinical diabetes by thiamine supplementation
is an emerging strategy to improve the treatment of early-
stage DN [28]. Studies of thiamine status in healthy people
have shown that urinary thiamine normalised to urinary
creatinine correlates positively with 24 h urinary excretion of
thiamine [29]. Twenty-four hour urinary excretion of thiamine
also correlates with dietary intake of thiamine [30]. Urinary
thiamine–creatinine ratio measured herein therefore relates
to dietary intake of thiamine and was increased approximate-
ly 2-fold in patients with type 2 diabetes and normoalbumi-
nuria only. This was also found in previous study of patients
with type 2 diabetes in the United Kingdom [8]. This may
reflect improved dietary advice and compliance with it of
some but not all patients with type 2 diabetes. Herein,
however, patients with type 2 diabetes stratified by ACR –
normoalbuminuria, microalbuminuria and albuminuria – had
similar duration of diabetes, HbA1c, blood pressure and lipids
(except triglycerides), suggesting that patients with micro-
albuminuria and albuminuria had progressed to incipient andf B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e x x x ( 2 0 1 1 ) x x x – x x x 7
DIAB-5357; No. of Pages 10overt DN more rapidly than those with normoalbuminuria.
Patients with microalbuminuria and albuminuria had lower
urinary excretion of thiamine than those with normoalbumi-
nuria (0.30 versus 0.46 mmol/g creatinine, P < 0.025). This may
reflect influence of dietary thiamine on rate of development of
DN with higher dietary thiamine intake linked to slower
progression of DN. This was found in the prospective Joslin
Kidney Study of patients with type 1 diabetes [31].
Thiamine status showed limited disturbance in patients
with type 2 diabetes, excepting 62% increase in urinary
excretion and 50% increase in FEthiamine in patients with
normoalbuminuria. The latter was also typical of all patients
with diabetes combined. In healthy people the plasma
concentration of thiamine was lower and FEthiamine higher
than found previously in a UK study although the urinary
excretion of thiamine was similar in the two populations [8].
Plasma thiamine concentration in patients with type 2
diabetes were similar to those found in patients with type 2
diabetes in Pakistan [6]. There was also a marked lower
increase in FEthiamine in patients with type 2 diabetes than
found in the UK study. The reasons for these disparities are not
clear but renal handling of thiamine was nevertheless
disturbed with increased washout of thiamine in patients
with type 2 diabetes in Indonesia. FEThiaminewas not correlated
with urinary excretion of thiamine, suggesting that increase in
FEThiamine was not due to increased dietary thiamine intake.
Increased FEThiamine occurs in both experimental and clinical
diabetes and is linked to decreased re-uptake of thiamine from
the glomerular filtrate in the renal tubules in the diabetic state
[8,27], likely linked to hyperglycemia-induced down regulation
of thiamine transporter proteins in renal proximal tubular
epithelial cells [32]. The positive regression of FEThiamine with
HbA1c is consistent with this mechanistic interpretation.
Thiamine supplements correct associated tissue specific
thiamine deficiency in diabetes (reviewed in [28]).
For vitamin B6, there was no evidence of increased
fractional excretion of B6 vitamers in patients with type 2
diabetes, suggesting renal mishandling similar to thiamine is
not present. The finding of increased plasma PLP patients
with type 2 diabetes may relate to changes in tissue storage of
PLP. The major pools of vitamin B6 storage are in the skeletal
muscle and liver [33]. A minor release of PLP from tissues in
the diabetic state may account for this increase. The finding of
increased plasma and urinary levels of 4-PA suggests there is
increased degradation of B6 vitamers in patients with type 2
diabetes. Urinary 4-PA normalised to urinary creatinine
correlates positively with 24 h urinary excretion of 4-PA
[34]. Increased urinary excretion of 4-PA in diabetes,
expressed as a percentage of total vitamin B6 excretion,
was not correlated with urinary excretion of pyridoxal,
suggesting that increased excretion of 4-PA is not linked to
dietary intake of vitamin B6. 4-PA is formed by oxidation of PL
catalysed by tissue oxidases [35]. The correlation of increased
urinary excretion of 4-PA with HbA1c suggests that increased
B6 vitamer degradation is linked to metabolic dysfunction in
hyperglycemia. Multiple regression analysis revealed asso-
ciations of urinary excretion of 4-PA with duration of
diabetes, suggesting that degradation of vitamin B6 may
increase in severity as diabetes progresses. Increased
degradation of vitamin B6 is a novel aspect of B-vitaminPlease cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
renal status, glycemic control and vascular inflammation. Diab Res Clindisturbance in diabetes that may be considered in assessing
requirement for vitamin supplementation.
Levels of vitamin B12 in patients with type 2 diabetes have
been studied in relation to mechanistic links to increased
plasma tHcy [12,13] and effects of metformin therapy [14,15].
Low plasma holotranscobalamin and high plasma MMA is an
indicator of vitamin B12 deficiency [26]; plasma holotransco-
balamin is considered now to be a better marker of vitamin B12
status than total plasma B12 concentration [36]. More recently,
the concept of metabolic resistance to vitamin B12 in diabetes
has been proposed to explain increased plasma levels of
vitamin B12 in the presence of markers of decreased functional
activity of the vitamin – increased tHcy, for example [37]. In
this study, patients with type 2 diabetes had increased total
cobalamin and holotranscobalamin in plasma. There was a
concomitant increase in tHcy but not of MMA. Plasma
holotranscobalamin in healthy subjects and patients with
type 2 diabetes and plasma MMA in all subjects groups were
similar to those of a large healthy human population [38],
suggesting there was likely limited voluntary supplementa-
tion of vitamin B12 in the study groups.
Increased plasma holotranscobalamin without decrease or
negative correlation with plasma tHcy but with negative
correlation with MMA in patients with type 2 diabetes is a
marker of vitamin B12 disturbance. Plasma holotranscobala-
min in healthy subjects correlates negatively with both tHcy
and MMA [38,39]. Increased plasma tHcy is thought to reflect
decreased methyl transfer to homocysteine mediated by
methylcobalamin and catalysed by methionine synthase
and decreased transsulfuration to cystathionine catalysed
by cystathionine-b-synthase in the cytosol of cells. Decreased
methionine synthase activity and transsulfuration was found
in patients with type 2 diabetes and microalbuminuria and
albuminuria [40]. Formation of MMA is decreased by increased
methyl transfer from methylmalonyl-CoA to form succinyl-
CoA in mitochondria mediated by the mitochondrial vitamin
B12 metabolite 50-deoxyadenosyl-cobalamin. Hence, increased
plasma holotranscobalamin and tHcy without increased MMA
suggests there may be decreased functional activity of
cobalamin, or vitamin B12 resistance, in the cytosolic but
not in mitochondrial compartments of tissues in patients with
type 2 diabetes – ‘‘cytosolic metabolic resistance’’ to vitamin
B12.
Positive correlations of plasma total cobalamin and
holotranscobalamin with plasma glucose and HbA1c suggests
hyperglycemia may be linked to impairment of cobalamin
metabolism. Multiple regression analysis revealed a positive
link of increased plasma holotranscobalamin with fasting
plasma glucose and CRP, suggesting both hyperglycemia and
vascular inflammation may be linked to metabolic resistance
to vitamin B12 in type 2 diabetes. Increased plasma total
cobalamin and holotranscobalamin in patients with type 2
diabetes may suggest hyperglycemia impairs tissue uptake of
vitamin B12. If this is indeed so, our findings are consistent
with mitochondria effectively scavenging residual vitamin B12
taken up from the cytoplasm to maintain metabolism of MMA.
These effects support and advance the concept of metabolic
resistance to vitamin B12 in diabetes [37].
Vascular inflammation is thought to be a characteristic and
mechanistic mediator of vascular disease in patients with typef B-vitamin status in people with type 2 diabetes in Indonesia—Link to
 Pract (2011), doi:10.1016/j.diabres.2011.10.042
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are plasma CRP and sVCAM-1. Plasma CRP has previously
been linked to BMI, glucose intolerance and microalbumi-
nuria in Western populations. In this study, plasma CRP was
only increased in patients with type 2 diabetes and micro-
albuminuria. Nevertheless, plasma CRP correlated positively
with BMI and TG. The positive link of sVCAM-1 to ACR and
negative link to GFR revealed the expected links of the marker
of endothelial dysfunction with decline in renal function.
Plasma sVCAM-1 was increased in patients with type 2
diabetes and albuminuria compared to healthy people – as
found previously [42]. In a similar study of 74 patients with
diabetes in the United Kingdom, however, we found 51% of
patients had sVCAM-1 levels higher than the normal range
maximum whereas only 11% of patients with type 2 diabetes
had sVCAM-1 levels above this level herein, which was
similar percentage as in healthy controls. Good glycemic
control and also genetic and dietary factors in the Indonesian
study population may be linked to low vascular inflammation
[41]. This study suggests that low grade inflammation is not a
marked characteristic of all populations of patients with type
2 diabetes.
A 2-month washout period was included in this study
between pre-screening and study entry to minimise the
effects of voluntary vitamin supplementation prior to entry
into the study. The half-life of thiamine in plasma is relatively
short (2 days) [43] and in tissues 9–18 days [44]. For vitamin B6 it
was reasoned that concentrations of B6 vitamers in human
subjects to adjust to new amounts of dietary intake within 10–
20 days [33] – which has also been evidenced experimentally
for plasma and RBCs pools of PLP [45,46]. The half-life of
vitamin B12 is ca. 400 days [47] and hence the 2-month washout
period does not provide correction for tissue loading of
vitamin B12 by voluntary supplementation. The half-life of
holotranscobalamin and total plasma cobalamin, however, is
markedly less – ca. 3 days [48]. The washout period of 2 months
provided for correction of B-vitamin levels after supplemen-
tation for thiamine, B6 vitamers and vitamin B12 (plasma
holotranscobalamin and total cobalamin only).
A high proportion of healthy people recruited for the study,
ca. 60%, had HbA1c indicative of pre-diabetes state of impaired
glucose tolerance (IGT). The age range was 47–65 years. The
prevalence of IGT in Indonesia assessed by oral glucose
tolerance test in 2009 for this age group was 13–18% [49].
Analysis of B-vitamin status in healthy people with pre-
diabetes IGT showed no significant disturbance of B-vitamin
status.
There is a possibility that patients with type 2 diabetes in
this study with microalbuminuria and albuminuria developed
nephropathy independent of the presence of diabetes. The
criteria for patients with type 2 diabetes and microalbumi-
nuria or albuminuria were a documented diagnosis of type 2
diabetes mellitus of 5 years and presence of microalbumi-
nuria or albuminuria on 2 or more occasions – including at pre-
screening and study entry. The Collaborative Study Group,
using entry criteria similar to these found that 94% of patients
with type 2 diabetes and nephropathy had diabetic glomer-
ulosclerosis on biopsy [50]. The presence of non-diabetic
nephropathy was, therefore, likely limited and the outcomes
of study groups type 2 diabetes with and microalbuminuria orPlease cite this article in press as: Adaikalakoteswari A, et al. Disturbance o
renal status, glycemic control and vascular inflammation. Diab Res Clinalbuminuria are indeed attributable to diabetic incipient and
overt nephropathy, respectively.
Assessing the effects of medication of patients with type 2
diabetes on B-vitamin status, there was no disturbance of B-
vitamin status with treatment by metformin, insulin nor
statins. Treatment with a-glucosidase inhibitors and sulfo-
nylureas was, however, linked to decreased plasma holo-
transcobalamin, and treatment with a-glucosidase inhibitors
also linked to decreased RBC concentration of PLP. Treatment
with ARBs/ACEIs was associated with increased plasma
thiamine concentration, suggesting that benefits of these
agents may also be associated with decreasing renal clearance
of thiamine. The number of patients in this study receiving
treatment with ARBs/ACEIs was small, however, and this
effect requires confirmation in a larger patient group.
The clinical significance of B-vitamin disturbance in
patients with type 2 diabetes found herein may be judged
from vitamin supplementation studies. Supplementation with
thiamine of patients with type 2 diabetes reversed early-stage
kidney disease – a response that may be linked to correcting
renal deficiency of thiamine linked to this increased thiamine
washout [28]. Previous studies of supplementation with
vitamins B6, B9 and B12 in patients with vascular disease or
diabetes found no effect of co-supplementation on death from
CVD, decreased risk of stroke and increased risk of unstable
angina (HOPE-2) study [12] and patients with type 1 or type 2
diabetes mellitus and advanced DN increased the rate of
decline in renal function (DIVINe study) [13]. Folate and
cyanide from cyanocobalamin treatment are possible factors
linked to adverse effects in the DIVINe study [16,17], which
may negate otherwise beneficial effects of vitamin B6 and B12
supplementation, but this requires further investigation.
Currently countering the effects of diabetes-induced renal
washout of thiamine by thiamine supplementation appears to
be the most important disturbance of B-vitamin metabolism
requiring correction for improved clinical outcome.
5. Conclusions
This study shows that there was increased FEthiamine in
patients with type 2 diabetes – suggesting renal mishandling of
thiamine, increased urinary excretion of 4-PA – indicative of
increased vitamin B6 degradation, and increased tHcy without
increased MMA in the presence of increased plasma total and
active vitamin B12, consistent with cytosolic metabolic
resistance to vitamin B12. There were also modest increases
of plasma CRP and sVCAM-1 in patients with type 2 diabetes
with microalbuminuria and albuminuria, respectively, sug-
gesting limited vascular inflammation. Therefore, in
Indonesia patients with type 2 diabetes – typical of the South
East Asian region, there is increased washout of thiamine,
degradation of vitamin B6 and cytosolic metabolic resistance
to vitamin B12 without marked vascular inflammation.
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